<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00233064</url>
  </required_header>
  <id_info>
    <org_study_id>MI-CP116</org_study_id>
    <nct_id>NCT00233064</nct_id>
  </id_info>
  <brief_title>Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis)</brief_title>
  <official_title>A Phase IV, Randomized, Double-Blind Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis) in Children at High Risk for the Development of Serious RSV Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to measure the rate of anti-palivizumab antibodies (also
      referred to as immune reactivity or immunogenicity) in subjects receiving either the liquid
      or lyophilized formulation of palivizumab. This study will compare the number and percentage
      of subjects with anti-palivizumab antibodies receiving either the liquid or lyophilized
      formulation of palivizumab.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The approved liquid formulation of palivizumab was developed to simplify preparation of the
      drug before injection. Both formulations of palivizumab have been shown to be bioequivalent
      in children 6 months of age or younger with a history of chronic lung disease. In previous
      studies of liquid palivizumab, immunogenicity was evaluated up to 2 months after dosing in
      adults, and 1 month after dosing in children. In this study, MI-CP116, immunogenicity will be
      evaluated between 4 and 6 months after the last dose of study drug, in order to provide data
      at a time point significantly distant from dosing when drug interference is minimal.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and Percentage of Participants With Immune Reactivity</measure>
    <time_frame>Day 240-300 follow up</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">417</enrollment>
  <condition>Chronic Lung Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Liquid Palivizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lyophilized Palivizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Lyophilized Palivizumab</intervention_name>
    <description>Patients will receive 15 mg/kg of lyophilized palivizumab administered intramuscularly every 30 days for a total of 5 injections.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Synagis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Liquid Palivizumab</intervention_name>
    <description>Patients will receive 15 mg/kg of liquid palivizumab administered intramuscularly every 30 days for a total of 5 injections.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Synagis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Medically stable child with chronic lung disease of prematurity who is ≤24 months of
             age at randomization OR child with premature birth (gestational age ≤35 weeks or less)
             and who is 6 months of age or younger at randomization

          -  Written informed consent obtained from the patient's parent(s) or legal guardian(s)

          -  The child must be able to complete the follow-up visit 4-6 months after the last dose
             of study drug

        Exclusion Criteria:

          -  Hospitalization at the time of randomization (unless discharge is anticipated within 3
             weeks)

          -  Be receiving mechanical ventilation at the time of study entry (including CPAP)

          -  Congenital heart disease (children with uncomplicated CHD [e.g., PDA, small septal
             defect] and children with complicated CHD who are currently anatomically and
             hemodynamically normal can be enrolled).

          -  Mother with HIV infection (unless the child has been proven to be not infected)

          -  Life expectancy &lt;6 months

          -  Known allergy to Ig products

          -  Acute respiratory or other acute infection or illness

          -  Previous reaction to IGIV, blood products, or other foreign proteins

          -  Receipt of lyophilized palivizumab, RSV-IG IV, or other RSV-specific monoclonal
             antibody, or any other polyclonal antibody (for example, Hepatitis B IG, IVIG, VZIG)
             within 3 months prior to randomization

          -  Any previous receipt of MEDI-524

          -  Participation in other investigational drug product studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Genny Losonsky, MD</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Birmingham Pediatric Associates</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consultants</name>
      <address>
        <city>Hoover</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Alabama School of Medicine</name>
      <address>
        <city>Tuscaloosa</city>
        <state>Alabama</state>
        <zip>35487</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>All for Kids Pediatric Clinic</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Medical Center</name>
      <address>
        <city>Foothill Ranch</city>
        <state>California</state>
        <zip>92610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edinger Medical Group</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doctors Medical Group</name>
      <address>
        <city>West Covina</city>
        <state>California</state>
        <zip>91790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Convenience Care</name>
      <address>
        <city>West Covina</city>
        <state>California</state>
        <zip>91791</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norwich Pediatric Group, P.C.</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Allergy Center at Brookstone</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physicians to Children and Adolescents</name>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peak Medical Research LLC</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Association of Fall River</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Woburn Pediatric Associates</name>
      <address>
        <city>Woburn</city>
        <state>Massachusetts</state>
        <zip>01801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Institute of Medicine</name>
      <address>
        <city>Livonia</city>
        <state>Michigan</state>
        <zip>41852</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Childrens Hospital</name>
      <address>
        <city>Paterson</city>
        <state>New Jersey</state>
        <zip>07503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maimonides Pediatric Pulmonology</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Carolina Children's &amp; Adult's Clinical Research Foundation/Purcell Clinic</name>
      <address>
        <city>Laurinburg</city>
        <state>North Carolina</state>
        <zip>28352</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capitol Pediatric And Adolescent Center</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Carolina Children's and Adult's Clinical Research Foundation</name>
      <address>
        <city>Sylva</city>
        <state>North Carolina</state>
        <zip>28779</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medcenter One/Q&amp;R Clinic</name>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dakota Clinic, Ltd. / Innvois Health</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trinity Medical Group-Health Center Medical Arts</name>
      <address>
        <city>Minot</city>
        <state>North Dakota</state>
        <zip>58701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Shelly David Senders, M.D., Inc.</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Cincinnati Pediatric Associates, Inc</name>
      <address>
        <city>Mason</city>
        <state>Ohio</state>
        <zip>45040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santiago Reyes, M.D.</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-State Pediatrics</name>
      <address>
        <city>Beaver Falls</city>
        <state>Pennsylvania</state>
        <zip>15010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Medical Center</name>
      <address>
        <city>Greenville</city>
        <state>Pennsylvania</state>
        <zip>16125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCP - Armstrong Pediatrics</name>
      <address>
        <city>Kittanning</city>
        <state>Pennsylvania</state>
        <zip>16201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Alliance of Latrobe</name>
      <address>
        <city>Latrobe</city>
        <state>Pennsylvania</state>
        <zip>15650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple Univ. Children's Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Alliance, Southwestern</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Hills Pediatrics</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Alliance, Southwestern</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Physician's Research, Inc.</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laurel Pediatrics</name>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <zip>15401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brown Clinic P.L.L.P./Northridge Clinic</name>
      <address>
        <city>Watertown</city>
        <state>South Dakota</state>
        <zip>57201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jackson Clinic</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holston Medical Group; Pediatrics at Meadowview Lane</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holston Medical Group; Pediatrics at Stone Plaza</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sadler Clinic</name>
      <address>
        <city>Conroe</city>
        <state>Texas</state>
        <zip>77304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Allergy/Immunology Associates, PA</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedPro Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Associates</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77087</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality Assurance Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wee Care Pediatrics</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bear Care Pediatrics</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Valley Pediatrics</name>
      <address>
        <city>Provo</city>
        <state>Utah</state>
        <zip>84604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Families First Pediatrics</name>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Pediatrics</name>
      <address>
        <city>Vienna</city>
        <state>Virginia</state>
        <zip>22180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WVU Department of Pediatrics</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monroe Clinic</name>
      <address>
        <city>Monroe</city>
        <state>Wisconsin</state>
        <zip>53566</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2005</study_first_submitted>
  <study_first_submitted_qc>October 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2005</study_first_posted>
  <results_first_submitted>October 2, 2008</results_first_submitted>
  <results_first_submitted_qc>October 27, 2008</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 28, 2008</results_first_posted>
  <last_update_submitted>January 7, 2010</last_update_submitted>
  <last_update_submitted_qc>January 7, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Genevieve Losonsky, M.D.</name_title>
    <organization>MedImmune Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palivizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 417 subjects were randomized into the study at 51 sites in the United States between 20 October 2005 and 02 October 2007.</recruitment_details>
      <pre_assignment_details>A total of 4 subjects at site #1022 who received all 5 doses of study drug (per drug accountability records) had no further information including case report form that could be obtained. These 4 subjects were excluded from all data analyses.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Liquid Palivizumab</title>
          <description>Liquid Palivizumab, 15 mg/kg IM q30 days X 5</description>
        </group>
        <group group_id="P2">
          <title>Lyophilized Palivizumab</title>
          <description>Lyophilized Palivizumab, 15 mg/kg IM q30 days X 5</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="211"/>
                <participants group_id="P2" count="202"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="197"/>
                <participants group_id="P2" count="190"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Relocation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved to Dom. Republic</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Liquid Palivizumab</title>
          <description>Liquid Palivizumab, 15 mg/kg IM q30 days X 5</description>
        </group>
        <group group_id="B2">
          <title>Lyophilized Palivizumab</title>
          <description>Lyophilized Palivizumab, 15 mg/kg IM q30 days X 5</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="211"/>
            <count group_id="B2" value="202"/>
            <count group_id="B3" value="413"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.56" spread="4.50"/>
                    <measurement group_id="B2" value="4.00" spread="4.16"/>
                    <measurement group_id="B3" value="4.29" spread="4.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="211"/>
                    <measurement group_id="B2" value="202"/>
                    <measurement group_id="B3" value="413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Chronic Lung Disease at Prematurity</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="176"/>
                    <measurement group_id="B2" value="176"/>
                    <measurement group_id="B3" value="352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gestational Age at Birth</title>
          <units>Weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.4" spread="2.7"/>
                    <measurement group_id="B2" value="32.7" spread="2.5"/>
                    <measurement group_id="B3" value="32.5" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight at Day 0</title>
          <units>Kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.326" spread="2.274"/>
                    <measurement group_id="B2" value="5.079" spread="2.264"/>
                    <measurement group_id="B3" value="5.205" spread="2.270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number and Percentage of Participants With Immune Reactivity</title>
        <description>Presence of anti-palivizumab antibodies</description>
        <time_frame>Day 240-300 follow up</time_frame>
        <population>Participants who received at least 2 doses of study drug and had at least 1 blood sample collected (at baseline or Study Day 240-300) were included in the analysis. This included 206 subjects in Arm 1 and 200 subjects in Arm 2. Of these subjects, 191 (Arm 1) and 188 (Arm 2) had adequate blood samples for analysis. This analysis was per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Liquid Palivizumab</title>
            <description>Liquid Palivizumab, 15 mg/kg IM q30 days X 5</description>
          </group>
          <group group_id="O2">
            <title>Lyophilized Palivizumab</title>
            <description>Lyophilized Palivizumab, 15 mg/kg IM q30 days X 5</description>
          </group>
          <group group_id="O3">
            <title>Combined Liquid/Lyophilized Palivizumab</title>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Participants With Immune Reactivity</title>
          <description>Presence of anti-palivizumab antibodies</description>
          <population>Participants who received at least 2 doses of study drug and had at least 1 blood sample collected (at baseline or Study Day 240-300) were included in the analysis. This included 206 subjects in Arm 1 and 200 subjects in Arm 2. Of these subjects, 191 (Arm 1) and 188 (Arm 2) had adequate blood samples for analysis. This analysis was per protocol.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.5"/>
                    <measurement group_id="O3" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The subject number of 200 per treatment group was derived to demonstrate a percentage of immune reactivity in either the liquid or lyophilized formulations of palivizumab of &lt;2-3% based on 95% confidence intervals [(0%; 0.00, 1.83), (0.5%; 0.01, 2.75), (1%; 0.12, 3.57)].</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Overall percentage of immune reactivity</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.0</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
            <estimate_desc>The number and percentage of subjects with immune reactivity at Study Day 240-300 were constructed using the Clopper-Pearson Method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The subject number of 200 per treatment group was derived to demonstrate a percentage of immune reactivity in either the liquid or lyophilized formulations of palivizumab of &lt;2-3% based on 95% confidence intervals [(0%; 0.00, 1.83), (0.5%; 0.01, 2.75), (1%; 0.12, 3.57)].</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Overall percentage of immune reactivity</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.0</ci_lower_limit>
            <ci_upper_limit>2.9</ci_upper_limit>
            <estimate_desc>The number and percentage of subjects with immune reactivity at Study Day 240-300 were constructed using the Clopper-Pearson Method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The subject number of 200 per treatment group was derived to demonstrate a percentage of immune reactivity in either the liquid or lyophilized formulations of palivizumab of &lt;2-3% based on 95% confidence intervals [(0%; 0.00, 1.83), (0.5%; 0.01, 2.75), (1%; 0.12, 3.57)].</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Overall percentage of immune reactivity</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.0</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
            <estimate_desc>The number and percentage of subjects with immune reactivity at Study Day 240-300 were constructed using the Clopper-Pearson Method.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events were collected from the time of the first study drug administration through Study Day 150. Adverse events were not collected in this study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Liquid Palivizumab</title>
          <description>Liquid Palivizumab, 15 mg/kg IM q30 days X 5</description>
        </group>
        <group group_id="E2">
          <title>Lyophilized Palivizumab</title>
          <description>Lyophilized Palivizumab, 15 mg/kg IM q30 days X 5</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="211"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Cleft Lip</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anal Fissure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Gastroesophageal Reflux Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Umbilical Hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Occult Blood Positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="211"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Infectious Croup</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="211"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Rotavirus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Failure to Thrive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Craniosynostosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Complex Partial Seizures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Convulsions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Respiratory Distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Only serious adverse events were collected as part of the safety evaluation. One death (asphyxia) occurred in the Lyophilized Palivizumab group; this event was judged not related to study drug.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Hasan S. Jafri, MD</name_or_title>
      <organization>MedImmune, LLC</organization>
      <phone>301-398-0000</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

